Dr. KSS MD PhD

Author Bio

Dr. KSS MD PhD
I am an MD with an additional PhD in biochemistry, and for the past 20 years, in addition to practicing, being a researcher, and conducting clinical trials, I have been investing in biotech companies. I earned my degrees at a top 10 US institution, where I was an NIH scholar and graduated with top honors. I have extensive post-doctoral research experience and am board certified in internal medicine and gastroenterology. I am a member of Phi Beta Kappa and Alpha Omega Alpha (academic honor societies, the latter in medicine) and am a Fellow of the American College of Physicians, the American equivalent of being FRCP in certain Anglophone countries. My hobbies are traveling (I have been to 100 countries), chamber music, literature, film and Asian pottery. My goal as a Stock Gumshoe contributor is to discuss companies and use discussions of their technology, their drugs or planned drugs, as ways of teaching about physiology and disease states, along with their issues and opportunities. Dr. KSS is a paid contributor to Stock Gumshoe, he has agreed to our trading restrictions but he chooses his own topics and his words and opinions are his own.

Author Archives

Cisco, Chang & Charlie Part 3

Sometimes literary gimmicks backfire. In May 2015, we premiered “Cisco, Chang & Charlie” (sans Oxford comma) as a James Joycean brooding on the letter C, third letter of the alphabet, in three iterations. At the time, three stocks whose names begin with C were vying for attention and prompting questions from readers. The original plan […]

Oncotutorial

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, and his words and opinions are his own. You can find his bio and his past articles on his Stock Gumshoe page.] “The universe (which others call the Library) is composed of an indefinite and […]

Long Idea of the Year

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. You can see all of his old articles and his most recent comments on his Stock Gumshoe page.] “Keep it quiet. (Go slow.) […]

Quickster: Update on Corbus

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He chooses his own topics, and his words and opinions are his own. He has agreed to our trading restrictions. To see all of his column and his latest comments, go to his Stock Gumshoe page.] [Author’s note: This commentary has been […]

The 12 Biotechs of Christmas: Six

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. All of his past articles and most recent comments are on his Stock Gumshoe page.] Let’s turn our attention today, in a mild […]

The 12 Biotechs of Christmas: Five

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. All of his past articles and most recent comments are on his Stock Gumshoe page.] Our fifth stock on this Christmas outing is […]

The 12 Biotechs of Christmas: Four

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. All of his past articles and most recent comments are on his Stock Gumshoe page.] It’s a warm Sunday afternoon a few months […]

The Twelve Biotechs of Christmas: Two

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. All of his past articles and most recent comments are on his Stock Gumshoe page.] After the New Year, we plan to look […]

Such A Pleasant Stay

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. All of his past articles and most recent comments are on his Stock Gumshoe page.] “Thanks to you I’m much obliged Such a […]

Sea of Tranquility

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. All of his past articles and most recent comments are on his Stock Gumshoe page.] “I live in the light of the bright summer […]

Recent Author Comments

On Cisco, Chang & Charlie Part 3
Thanks zz.[...]
On Cisco, Chang & Charlie Part 3
yes....planning to attend,[...]
On Is Aurinia's Supremacy in Lupus Nephritis Threatened by Glaxo's Benlysta?
The entire float has now officially traded for the day.[...]
On Is Aurinia's Supremacy in Lupus Nephritis Threatened by Glaxo's Benlysta?
OK, Jammin.....which island are you buying THIS time???[...]
On Rodman and Renshaw Presentation Notes, Day Two
I agree with you. She is the strongest part of the $PSDV long thesis.[...]
On Cisco, Chang & Charlie Part 3
That article is a Stat-Plus article behind a paywall, and sadly I'll not pay to read their raker of muck's musings. Portola did NOT massage phase 3 failure, and Feuerstein, neither doctor, scientist nor statistician, isn't qualified to make such a call. Lo[...]
On Cisco, Chang & Charlie Part 3
Well, what's YOUR view of $TTOO? What prompts you to ask? Do you have a position in shares?[...]
On Cisco, Chang & Charlie Part 3
Sorry....I missed that comment. But had I seen it, I would have said, I think, that I was ready to go long finally after two years of $CAPR being in a wasteland. Rumors have been swirling that they've really made these DMD patients feel better...and if the[...]
On Is Aurinia's Supremacy in Lupus Nephritis Threatened by Glaxo's Benlysta?
Honor roll post.[...]
On Is Aurinia's Supremacy in Lupus Nephritis Threatened by Glaxo's Benlysta?
Thanks for letting us know what you're doing....I like when readers do that. I think you've made excellent decisions.[...]
On Is Aurinia's Supremacy in Lupus Nephritis Threatened by Glaxo's Benlysta?
What does the data say about intraocular pressure measurement as a screening test for glaucoma? http://www.bmj.com/content/358/bmj.j3889[...]
On Is Aurinia's Supremacy in Lupus Nephritis Threatened by Glaxo's Benlysta?
The I-Phone, which uses a different proprietary fingerprint scanner, is killing FPC. This Swedish tech company was 2 years ago amazingly promising, but has become blighted by old-boy insider fiascoes, competition, doubt as to prospects from aggressive Swed[...]
On Is Aurinia's Supremacy in Lupus Nephritis Threatened by Glaxo's Benlysta?
A successful outcome, as predicted here a couple of weeks back. Lefamulin is a worthy antibiotic, but the bar wasn't raised very high for this study. NP Nabriva. I appreciate readers who had pointed out the upcoming catalyst.[...]
On Is Aurinia's Supremacy in Lupus Nephritis Threatened by Glaxo's Benlysta?
What makes for a GOOD clinical trial site? http://ascopubs.org/doi/pdf/10.1200/jop.2010.000156[...]
On Oncotutorial
When I see Soaking Awful mentioned in a post, I stop reading that post immediately and move on to the next one. Life's too short to spend it drinking cheap wine.[...]
On Is Aurinia's Supremacy in Lupus Nephritis Threatened by Glaxo's Benlysta?
The slide I recall seeing pertaining to $ARTH clinical trials is not in this deck taken from the website.[...]
On Is Aurinia's Supremacy in Lupus Nephritis Threatened by Glaxo's Benlysta?
Yes, we need to clarify that. My recollection is fairly vivid that he was speaking of a trial going on now to qualify the agent for internal use. As I recall, he put up a powerpoint slide stating this, stating for internal use. I'm not sure I know off the [...]
On Is Aurinia's Supremacy in Lupus Nephritis Threatened by Glaxo's Benlysta?
Let's not forget that for many bacteria, including certain pathogens, oxygen is highly toxic. The anaerobes prefer oxygen-free conditions. Example: C.diff. Various medical entrepreneurs have schemed ways of delivering oxygen into the colon as a way to kill[...]
On Is Aurinia's Supremacy in Lupus Nephritis Threatened by Glaxo's Benlysta?
It does mean rather a lot. If he can genuinely abstain for 30 days, he's not an alcoholic. And it's quite possible he isn't. He may be a problem drinker, a binge drinker, or someone with a personality disorder who impulse drinks. He may be bipolar and be u[...]
On Is Aurinia's Supremacy in Lupus Nephritis Threatened by Glaxo's Benlysta?
Yes, and those remain reasonable parameters. He didn't revisit that subject at all when I heard him last week. I thought I heard him indicate, however, that a stockpile of AC5 has been mfg'd, so perhaps there would not be a lead time on the basis. But he n[...]

This site and Stock Gumshoe publications and authors do not offer individual financial, investment, medical or other advice. Nothing on this site should ever be considered to be personal advice, research or an invitation to buy or sell any securities. We also make mistakes and bad decisions sometimes, and our reasoning or data should be checked against trusted sources before they inform your investing decisions. Choices regarding how to invest your money or otherwise manage your life or finances are yours, we share only our analysis and opinion and all authors or commenters are individually responsible for the words and opinions they share here. Please read our important disclaimers and policies. Stock Gumshoe is supported by subscribers and by sponsors and advertisers. Stock Gumshoe's employee authors will disclose holdings in any stock covered at time of publication and will not trade in any stocks written about for at least three days after publication. Please see below for complete disclosure, disclaimer and policy information.